A. Zaucha-Prażmo, E. Sadurska, K. Drabko, J. Kowalczyk
{"title":"Can we find a good biochemical marker of early cardiotoxicity in children treated with haematopoietic stem cell transplantation?","authors":"A. Zaucha-Prażmo, E. Sadurska, K. Drabko, J. Kowalczyk","doi":"10.5114/wo.2016.61563","DOIUrl":null,"url":null,"abstract":"Cardiotoxicity is one of the complications following haematopoietic stem cell transplantation (HSCT), but its diagnosis may be hampered due to the presence of different post-transplant comorbidities. The aim of the study was to assess the incidence of cardiac complications and the significance of biochemical markers (NT-proBNP, ANP, ET-1, and TnI) and ECHO systolic and diastolic parameters analysis in children treated with HSCT. Thirty consecutive children (median age 9.6 years) were included in the study. The control group consisted of 14 healthy children (median age of 10.9 years). None of the transplanted children developed clinical cardiotoxicity. Median ET-1 and NT-proBNP plasma levels were elevated when compared to controls in at least 3 out of 4 analysed time points, median ANP levels differed only in one time point, and no difference was found between median TnI values in all analysed time points. Echocardiographic systolic parameters were within the normal range, while median E/A ratio assessed before HSCT, on day +30, and +100 post-transplant was statistically lower in HSCT patients (respectively, 1.34, 1.37, and 1.42 vs. 1.73). It confirms the need for careful follow up in patients who have received chemotherapy and have been treated with HSCT.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"2016 1","pages":"220 - 224"},"PeriodicalIF":0.0000,"publicationDate":"2016-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/wo.2016.61563","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Cardiotoxicity is one of the complications following haematopoietic stem cell transplantation (HSCT), but its diagnosis may be hampered due to the presence of different post-transplant comorbidities. The aim of the study was to assess the incidence of cardiac complications and the significance of biochemical markers (NT-proBNP, ANP, ET-1, and TnI) and ECHO systolic and diastolic parameters analysis in children treated with HSCT. Thirty consecutive children (median age 9.6 years) were included in the study. The control group consisted of 14 healthy children (median age of 10.9 years). None of the transplanted children developed clinical cardiotoxicity. Median ET-1 and NT-proBNP plasma levels were elevated when compared to controls in at least 3 out of 4 analysed time points, median ANP levels differed only in one time point, and no difference was found between median TnI values in all analysed time points. Echocardiographic systolic parameters were within the normal range, while median E/A ratio assessed before HSCT, on day +30, and +100 post-transplant was statistically lower in HSCT patients (respectively, 1.34, 1.37, and 1.42 vs. 1.73). It confirms the need for careful follow up in patients who have received chemotherapy and have been treated with HSCT.
心脏毒性是造血干细胞移植(HSCT)后的并发症之一,但由于存在不同的移植后合并症,其诊断可能受到阻碍。本研究的目的是评估心脏并发症的发生率以及生化指标(NT-proBNP、ANP、ET-1和TnI)和ECHO收缩期和舒张期参数分析在接受HSCT治疗的儿童中的意义。连续30名儿童(中位年龄9.6岁)被纳入研究。对照组为14例健康儿童(中位年龄10.9岁)。没有一例移植儿童出现临床心脏毒性。与对照组相比,在4个分析时间点中至少有3个ET-1和NT-proBNP中位血浆水平升高,ANP中位水平仅在一个时间点存在差异,在所有分析时间点中,TnI中位值之间没有差异。超声心动图收缩期参数在正常范围内,而HSCT患者在移植前、移植后+30天和+100天评估的中位E/A比值在统计学上较低(分别为1.34、1.37和1.42 vs. 1.73)。它证实了对接受过化疗并接受过造血干细胞移植的患者进行仔细随访的必要性。